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Background: We sought to investigate the role of adjunctive cilostazol loading in addition to aspirin and clopidogrel for the platelet 
responsiveness to antiplatelet agents. 
Methods: From Apr. 2008 to Sep. 2009, 50 consecutive, acute coronary syndrome, patients undergoing PCI with drug-eluting stents were enrolled 
and assigned to receive 300-mg loading dose (LD) of aspirin and clopidogrel with or without 200-mg loading dose of cilostazol. All LD of antiplatelet 
agents were given at least 3 hours before PCI procedure and followed by dual or triple maintenance dose therapy. Platelet function tests were 
performed just before PCI and 24 hours and 30 days after PCI using light transmittance aggregometer (LTA), VerifyNow assay. 
Results: Comparing baseline and angiographic characteristics between two groups, there were no significant differences. Laboratory results 
revealed that adjunctive loading dose of 200-mg cilostazol induce more potent inhibition of platelet function as compared to dual LD regimen at 
each time point (figure). Cilostazol not only reduce the incidence of clopidogrel resistance but also decrease the prevalence of aspirin resistance.
Conclusion: Adjunctive loading dose of 200-mg cilostazol followed by triple antiplatelet therapy 
of maintenance dose could improve platelet responsiveness in the peri- and post-procedural phase.
